<DOC>
	<DOCNO>NCT01585220</DOCNO>
	<brief_summary>This study design randomize , multi-center , double Masked , match Pairs , active-controlled clinical trial . Subjects voluntarily sign informed consent judge eligible study intradermally inject study device comparator device . Subjects randomize receive injection study device comparator device nasolabial fold . Efficacy evaluate base change Wrinkle Severity Rating Scale ( WSRS ) baseline . Safety assess base 24 week follow visit subject diary give subject first 2 week injection . Any uncomfortable thing adverse event investigate subeject diary follow visit .</brief_summary>
	<brief_title>Efficacy Safety Study Neuramis Correction Nasolabial Fold</brief_title>
	<detailed_description />
	<criteria>1 . Men woman age 30 75 2 . Subjects want correct his/her nasolabial fold attain grade 3 4 Wrinkle Severity Rating Scale ( WSRS ) nasolabial fold 3 . Subjects whose nasolabial fold visually symmetric 4 . Subjects agree restrict treatment wrinkle correction lower orbital rim area duration study 5 . Subjects understand comply instruction visit schedule 6 . Subjects voluntarily decide participation study sign informed consent 1 . Subjects anticoagulant therapy ( exclude lowdose aspirin therapy ( 100mg , maximum 300mg/day dose ) ) within 2 week screen date 2 . Subjects previous treatment low orbital rim wrinkle correction ( e.g. , face lift , soft tissue augmentation , medium depth peel , dermal photorejuvenation ) within 6 month screen date 3 . Subjects treat calcium hydroxyapatite NLF area within year screen date 4 . Subjects dermal augmentation permanent implant ( e.g. , silicone , SoftformÂ® ) NLF area 5 . Subjects scar skin lesion affect efficacy NLF area 6 . Subjects anaphylaxis severe combine allergy allergy lidocain hyaluronic acid 7 . Subjects history keloid formation hypertrophic scar 8 . Subjects skin disorder wound infection NLF area 9 . Subjects participate clinical trial within 30 day screen date 10 . The childbearing subject disagree medically acceptable contraception ( e.g. , condom , oral contraceptive continue least 3 month , contraceptive injection insertion , intrauterine contraceptive device ) 11 . Pregnant lactating subject 12 . Patients eligible study medical discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>WSRS</keyword>
	<keyword>GAIS</keyword>
	<keyword>HA filler</keyword>
	<keyword>filler</keyword>
</DOC>